How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

148,856 results for

cancer AND (breast OR prostate OR colon) AND (NOT brain)

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

2. Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer

Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer Advice for NHSScotland Colon capsule endoscopy (CCE-2 (...) of the colon, called a polyp. Early detection and removal of precancerous polyps is very effective for preventing colorectal cancer. People in Scotland with suspected colorectal polyps/cancer are currently referred for an optical colonoscopy or CT colonography if optical colonoscopy is not clinically appropriate. Colon capsule endoscopy (CCE-2) is a new technique for examining the colon using an ingestible capsule containing one or more cameras. Health technology Optical colonoscopy, CT colonography

2019 Evidence Notes from Healthcare Improvement Scotland

3. Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer (PubMed)

Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer Cancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostate cancer.

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

4. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (PubMed)

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

5. Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients. (PubMed)

Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients. To date, research on stigmatization among cancer patients and related psychosocial consequences has been scarce and mostly based on small and highly selected samples. We investigated stigmatization and its impact on quality of life among a large sample including four major tumor entities.We assessed 858 patients with breast, colon (...) (isolation, social rejection, financial insecurity and internalized shame) were in the lower and middle range, with the highest values found for isolation. Stigmatization was lowest among prostate cancer patients. Stigmatization predicted all five areas of QoL among breast cancer patients (p < .05), but only affected emotional functioning (p < .01) among lung cancer patients.We found an inverse relationship between perceived cancer-related stigmatization and various dimensions of QoL, with variation

Full Text available with Trip Pro

2017 BMC Cancer

6. Life after breast, prostate, and colon cancer: Primary care's role. (PubMed)

Life after breast, prostate, and colon cancer: Primary care's role. When patients survive cancer, they eventually come back to their primary care physicians. This group has special needs, including surveillance for recurrent and new cancer, health promotion, and interventions to mitigate the lingering effects of the cancer and the adverse effects of its treatment.Copyright © 2017 Cleveland Clinic.

Full Text available with Trip Pro

2017 Cleveland Clinic Journal of Medicine

7. Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

2017 European Medicines Agency - EPARs

8. Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer. (PubMed)

Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer. Physical activity has been shown to reduce the risk of colon, endometrial and postmenopausal breast cancer. The aim of this study was to quantify the proportion of the cancer burden in the Nordic countries linked to insufficient levels of leisure time physical activity and estimate the potential for cancer prevention for these three sites (...) -hours/week), low deficit (9 to <15 MET-hours/week), medium deficit (3 to <9 MET-hours/week) and high deficit (<3 MET-hours/week).If no one had insufficient levels of physical activity, about 11,000 colon, endometrial and postmenopausal breast cancer cases could be avoided in the Nordic countries in a 30-year period, which is 1% of the expected cases for the three cancer types. With a 50% reduction in all deficit groups by 2025 or a 100% reduction in the group of high deficit, approximately 0.5

2019 European Journal of Cancer

9. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer (PubMed)

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer Two functional SNPs (SNP285G > C; rs117039649 and SNP309T > G; rs2279744) have previously been reported to modulate Sp1 transcription factor binding to the promoter of the proto-oncogene MDM2, and to influence cancer risk. Recently, a third SNP (SNP55C > T; rs2870820) was also reported to affect Sp1 binding and MDM2 transcription. In this large population based case-control study, we (...) genotyped MDM2 SNP55 in 10,779 Caucasian individuals, previously genotyped for SNP309 and SNP285, including cases of colon (n = 1,524), lung (n = 1,323), breast (n = 1,709) and prostate cancer (n = 2,488) and 3,735 non-cancer controls, as well as 299 healthy African-Americans. Applying the dominant model, we found an elevated risk of colon cancer among individuals harbouring SNP55TT/CT genotypes compared to the SNP55CC genotype (OR = 1.15; 95% CI = 1.01-1.30). The risk was found to be highest for left

Full Text available with Trip Pro

2016 Scientific reports

10. Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases

Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

12. Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer: A case report. (PubMed)

Metachronous triple primary neoplasms with primary prostate cancer, lung cancer, and colon cancer: A case report. Multiple primary neoplasms (MPNs) are rare. Most MPNs are double, and triple primary neoplasms are extremely rarer. Here, we describe a case of a 66-year-old man diagnosed with metachronous triple primary neoplasms with primary prostate cancer, lung cancer and colon cancer.The patient complained of dysuria in January 2015, and he underwent transurethral resection of the prostate (...) of the lung showed moderately differentiated adenocarcinoma with epidermal rowth factor receptor exon 21 mutation.Metachronous triple primary neoplasms with primary prostate cancer, lung cancer and colon cancer.The patient underwent surgical resection of the right upper lobe of the lung, postoperative stage was T1bN0M0 (stage IA). After 8 cycles of chemotherapy with modified FOLFOX6 regimen (oxaliplatin 85 mg/m, leucovorin 400 mg/m, 5-fluorouracil 400 mg/m on day 1, followed by 5-fluorouracil 2400 mg/m

Full Text available with Trip Pro

2018 Medicine

13. Family history of breast or prostate cancer and prostate cancer risk. (PubMed)

Family history of breast or prostate cancer and prostate cancer risk. Breast and prostate cancer co-occur in families, and women with a family history of prostate cancer are at increased breast cancer risk. Prostate cancer is among the most heritable cancers, but few studies have investigated its association with familial breast cancer. The objective of this study is to investigate the extent to which familial breast or prostate cancer in first-degree relatives increases prostate cancer risk.A (...) prospective study of 37,002 U.S. men in the Health Professionals Follow-up Study. During the 16-year follow-up to 2012, 4,208 total and 344 lethal cases were diagnosed. Using cause-specific hazards regression, we estimated the multivariable HRs and 95% confidence intervals (CI) for associations between familial breast or prostate cancer and total and lethal prostate cancer.Those with familial breast cancer had a 21% greater risk of prostate cancer overall (95% CI, 1.10-1.34), and a 34% greater risk

2018 Clinical Cancer Research

14. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

2017 Health Quality Ontario

15. Prostate cancer: diagnosis and management

bicalutamide monotherapy (longer than 6 months), offer prophylactic radiotherapy to both breast buds within the first month of treatment. Use a single fraction of 8 Gy using orthovoltage, or electron beam radiotherapy. [2008] [2008] 1.4.17 If radiotherapy does not prevent gynaecomastia, consider weekly tamoxifen [5] . [2008] [2008] F Fatigue atigue 1.4.18 T ell people who are starting androgen deprivation therapy that fatigue is a Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights (...) Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Article Text Therapeutics/Prevention Randomised controlled trial Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Philipp Dahm 1 , 2 , Dragan Ilic 3 , Timothy Wilt 4 , 5 Statistics from Altmetric.com Commentary

2017 Evidence-Based Medicine (Requires free registration)

17. Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer. (PubMed)

Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer. The possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent. The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients. The recent availability of selective AR inhibitors (e.g. bicalutamide, enzalutamide, apalutamide) approved for the treatment (...) of prostate cancer has opened up the possibility to use them in BC patients whose tumors express AR. However, AR appears to have various functions according to the BC subtype, e.g. ER-positive or triple negative BC and the patient prognosis is different on the basis of the presence or absence of estrogen and progesterone receptors. Moreover, a different AR expression was seen according to the various ethnicities. Of note, in population at low economical income, the availability of anti-AR compounds at low

2019 Seminars in cancer biology

18. Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients

Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02655952 Recruitment Status : Completed First Posted : January 14, 2016 Last Update Posted : December 28, 2018 Sponsor: WntResearch AB Information provided by (Responsible

2016 Clinical Trials

20. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate (PubMed)

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate The MDM2 promoter region contains several polymorphisms, some of which have been associated with MDM2 expression, cancer risk and age at cancer onset. del1518 (rs3730485) is an indel polymorphism residing in the MDM2 promoter P1 and is in almost complete linkage disequilibrium with the MDM2 promoter P2 polymorphism SNP309T>G (rs2279744). Cancer risk (...) assessments of del1518 have previously been conducted in relatively small Chinese populations only. In this study we assessed the genotype distribution of del1518 among healthy Caucasians, African Americans and Chinese, and we estimated the Odds Ratios (OR) for incident cancer of the breast, colon, lung and prostate (n=7,081) as compared to controls (n=3,749) in a large Caucasian (Norwegian) cohort.We found the genotypes of the del1518 to vary significantly between healthy Caucasians, African-Americans

Full Text available with Trip Pro

2016 Oncotarget

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>